Breaking News Instant updates and real-time market news.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

09:10
11/23/16
11/23
09:10
11/23/16
09:10

Morgan Stanley expects big reversal today in Biogen shares

Morgan Stanley Matthew Harrison expects shares of Biogen (BIIB) to end the trading day flat or slightly higher. The stock is currently down $26.61, or 8%, to $291.50 in pre-market trading. With Biogen's aducanumab more potent than Eli Lilly's solanezumab, the Alzheimer's drug still has potential for success, Harrison tells investors in a research note. He points out that Lilly management noted that "the study results, including many secondary clinical endpoints, directionally favored solanezumab." Harrison sees hope in the amyloid hypothesis. The analyst has an Overweight rating on Biogen.

  • 29

    Nov

BIIB Biogen
$318.11

-0.21 (-0.07%)

11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.

TODAY'S FREE FLY STORIES

AZN

AstraZeneca

$25.82

-0.07 (-0.27%)

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
AstraZeneca says data presented shows TAGRISSO superiority over chemotherapy »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 16

    Feb

EARS

Auris Medical

07:05
12/06/16
12/06
07:05
12/06/16
07:05
Hot Stocks
Auris Medical on track to resume enrollment of Keyzilen Phase 3 trial »

Auris Medical Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Earnings
Synchronoss sees FY17 pro forma EPS $2.45-$2.60 for combined entity »

May not compare to…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

CHTR

Charter

$270.93

4.26 (1.60%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Charter initiated  »

Charter initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MDGN

Medgenics

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Initiation
Medgenics initiated  »

Medgenics initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AM

Antero Midstream

$28.48

-0.1 (-0.35%)

07:04
12/06/16
12/06
07:04
12/06/16
07:04
Upgrade
Antero Midstream rating change  »

Antero Midstream upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$39.86

0.17 (0.43%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Upgrade
HSBC rating change  »

HSBC upgraded to Equal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGTX

TG Therapeutics

$5.70

0.2 (3.64%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
TG Therapeutics GENUINE Phase 3 study reaches target enrollment »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to divest part of activation business to Sequential for $146M »

Synchronoss is also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:03
12/06/16
12/06
07:03
12/06/16
07:03
Hot Stocks
Synchronoss to acquire Intralinks for $13/share, or $821M in equity value »

Synchronoss Technologies…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

TEVA

Teva

$37.04

0.51 (1.40%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Recommendations
Teva analyst commentary  »

Wells views departure of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

NVCN

Neovasc

$1.42

0.56 (65.12%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Neovasc provides update on Tiara transcatheter mitral valve »

Neovasc provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDS

GDS Holdings

$9.93

-0.07 (-0.70%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Initiation
GDS Holdings initiated  »

GDS Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$49.00

1.81 (3.84%)

, IL

Intralinks

$11.27

0.11 (0.99%)

07:02
12/06/16
12/06
07:02
12/06/16
07:02
Hot Stocks
Breaking Hot Stocks news story on Synchronoss, Intralinks »

Synchronoss to acquire…

SNCR

Synchronoss

$49.00

1.81 (3.84%)

IL

Intralinks

$11.27

0.11 (0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

KKR

KKR

$15.67

0.19 (1.23%)

, BX

Blackstone

$26.40

0.54 (2.09%)

07:01
12/06/16
12/06
07:01
12/06/16
07:01
Hot Stocks
KKR to acquire Optiv Security from investors, including fund managed by Blackstone »

Optiv Security, a…

KKR

KKR

$15.67

0.19 (1.23%)

BX

Blackstone

$26.40

0.54 (2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 13

    Dec

AZO

AutoZone

$776.42

-7.32 (-0.93%)

07:00
12/06/16
12/06
07:00
12/06/16
07:00
Earnings
AutoZone reports Q1 EPS $9.36, consensus $9.31 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

ROP

Roper Technologies

$181.64

-0.68 (-0.37%)

, PROJ

Deltek

06:59
12/06/16
12/06
06:59
12/06/16
06:59
Hot Stocks
Roper Technologies to buy Deltek in all cash transaction valued at $2.8B »

Roper Technologies (ROP)…

ROP

Roper Technologies

$181.64

-0.68 (-0.37%)

PROJ

Deltek

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$228.55

5.19 (2.32%)

06:59
12/06/16
12/06
06:59
12/06/16
06:59
Periodicals
Goldman Sachs leads financing round in Canadian startup Hubba, WSJ says »

Goldman Sachs led a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ROP

Roper Technologies

$181.64

-0.68 (-0.37%)

, PROJ

Deltek

06:57
12/06/16
12/06
06:57
12/06/16
06:57
Hot Stocks
Breaking Hot Stocks news story on Roper Technologies, Deltek »

Roper Technologies to buy…

ROP

Roper Technologies

$181.64

-0.68 (-0.37%)

PROJ

Deltek

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBB

Cincinnati Bell

$21.05

0.7 (3.44%)

06:56
12/06/16
12/06
06:56
12/06/16
06:56
Downgrade
Cincinnati Bell rating change  »

Cincinnati Bell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

BCS

Barclays

$10.97

0.27 (2.52%)

, DB

Deutsche Bank

$16.66

0.92 (5.85%)

06:56
12/06/16
12/06
06:56
12/06/16
06:56
Periodicals
Barclays energy trading exit a worry for cash-strapped producers, Reuters says »

Barclays' (BCS) exit…

BCS

Barclays

$10.97

0.27 (2.52%)

DB

Deutsche Bank

$16.66

0.92 (5.85%)

RBS

RBS

$5.03

0.12 (2.44%)

GS

Goldman Sachs

$228.55

5.19 (2.32%)

JPM

JPMorgan

$83.26

1.66 (2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 10

    Jan

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

RCII

Rent-A-Center

$11.91

0.38 (3.30%)

06:55
12/06/16
12/06
06:55
12/06/16
06:55
Downgrade
Rent-A-Center rating change  »

Rent-A-Center downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LSCC

Lattice Semiconductor

$7.10

0.16 (2.31%)

06:54
12/06/16
12/06
06:54
12/06/16
06:54
Periodicals
U.S. politicians request block of $1.3B Chinese buyout of Lattice, Reuters says »

More than 20 U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RES

RPC, Inc.

$21.63

0.31 (1.45%)

06:53
12/06/16
12/06
06:53
12/06/16
06:53
Downgrade
RPC, Inc. rating change  »

RPC, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTEN

Patterson-UTI

$28.78

0.69 (2.46%)

06:53
12/06/16
12/06
06:53
12/06/16
06:53
Downgrade
Patterson-UTI rating change  »

Patterson-UTI downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.